Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2025-06-10

FDA Approved: SODIUM POLYSTYRENE SULFONATE — Original Application (Burel Pharmaceuticals, LLC)

View source ↗

Summary

FDA approved the original application for sodium polystyrene sulfonate, a generic version by Burel Pharmaceuticals, LLC, for the management of hyperkalemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Sodium polystyrene sulfonate (Sodium polystyrene sulfonate)

Snippet

ORIG AP for SODIUM POLYSTYRENE SULFONATE (SODIUM POLYSTYRENE SULFONATE)